Annual report pursuant to Section 13 and 15(d)

Royalty and other income

v3.20.2
Royalty and other income
12 Months Ended
Jul. 31, 2020
Other Income and Expenses [Abstract]  
Royalty and other income

Note 14 - Royalty and other income


The Company had a license agreement with Qiagen that began in 2005, whereby the Company earned quarterly running royalties on the net sales of Qiagen products subject to a license until the underlying patent expired in April 2018. During the years ended July 31, 2020, 2019 and 2018, the Company recorded royalty income under the agreement of approximately $0, $0 and $712 respectively, which is included in the Life Sciences products segment.